Genetic Association Analysis Implicates Six MicroRNA-Related SNPs With Increased Risk of Breast Cancer in Australian Caucasian Women
Description
Introduction: Breast cancer (BC), a heterogeneous disease, features microRNA-related single nucleotide polymorphisms (miRSNPs) as underlying factors of BC development, thus providing targets for novel diagnostic and therapeutic strategies. This study investigated miRSNPs in BC susceptibility in Australian Caucasian women. Patients and Methods: The study population included patients 33 to 80 years of age stratified by molecular subtypes of breast tumors (luminal A, 47.59%), stage (stage I, 36.96%), tumor-type (ductal, 44.95%), grading (intermediate, 35.52%), size (10.1-25 mm, 31.14%), and lymph node (sentinel negative, 38.93%). Sixty-five miRSNPs underwent allelic analysis in two independent case–control cohorts (GU-CCQ-BB, 377 cases and 521 controls; GRC-BC, 267 cases and 201 controls) using a MassARRAY platform. GU-CCQ-BB, GRC-BC, and the combined populations (BC-CA) (644 cases and 722 controls) underwent independent statistical analysis. Results: In the GU-CCQ-BB population, miRSNPs TET2-rs7670522, ESR1-rs2046210, FGFR2-rs1219648, MIR210-rs1062099, HIF1A-rs2057482, and CASC16-rs4784227 were found to be associated with increased BC risk (P ≤.05). Only ESR1-rs2046210 was also significantly associated (P ≤.05) when replicated in the GRC-BC and BC-CA populations. No significant association was correlated with BC-clinical features (pathological types and ER/PR/HER2 status); however, MIR210-rs1062099 was found to be significantly associated (P ≤.05) with age (>50 years) in the GU-CCQ-BB cohort. Conclusion: This is the first study to demonstrate the association of MIR210-rs1062099 and TET2-rs7670522 with increased BC risk. Additionally, four previously reported SNPs (ESR1-rs2046210, FGFR2-rs1219648, HIF1A-rs2057482, and CASC16-rs4784227) were confirmed as BC risk variants. Replication and functional studies in larger Caucasian cohorts are necessary to elucidate the role of these miRSNPS in the development of BC.
Impact and interest:
Citation counts are sourced monthly from Scopus and Web of Science® citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.
| ID Code: | 210879 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Item Type: | Contribution to Journal (Journal Article) | ||||||||||
| Refereed: | Yes | ||||||||||
| ORCID iD: |
|
||||||||||
| Additional Information: | Funding Information: This work was supported by funding from the Genomics Research Centre at Institute of Health and Biomedical Innovation, Queensland University of Technology, and by infrastructure purchased with Australian Government EIF Super Science Funds as part of the Therapeutic Innovation Australia–Queensland Node project, with equipment, staff, and reagents supported by National Collaborative Research Infrastructure Strategy government funding and the Queensland Cancer Registry. | ||||||||||
| Measurements or Duration: | 10 pages | ||||||||||
| Keywords: | Breast Cancer, Genetic Association Study, Genotyping, microRNA (miRNA), Single Nucleotide Polymorphism (SNP) | ||||||||||
| DOI: | 10.1016/j.clbc.2021.03.012 | ||||||||||
| ISSN: | 1526-8209 | ||||||||||
| Pure ID: | 85619392 | ||||||||||
| Divisions: | Current > Research Centres > Centre for Genomics and Personalised Health Current > QUT Faculties and Divisions > Academic Division Current > QUT Faculties and Divisions > Faculty of Health Current > Schools > School of Biomedical Sciences |
||||||||||
| Funding Information: | This work was supported by funding from the Genomics Research Centre at Institute of Health and Biomedical Innovation, Queensland University of Technology, and by infrastructure purchased with Australian Government EIF Super Science Funds as part of the Therapeutic Innovation Australia–Queensland Node project, with equipment, staff, and reagents supported by National Collaborative Research Infrastructure Strategy government funding and the Queensland Cancer Registry. | ||||||||||
| Copyright Owner: | 2021 Elsevier Inc. | ||||||||||
| Copyright Statement: | This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au | ||||||||||
| Deposited On: | 04 Jun 2021 03:17 | ||||||||||
| Last Modified: | 03 Apr 2024 08:43 |
Export: EndNote | Dublin Core | BibTeX
Repository Staff Only: item control page
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)